Drug profile · INN
erlotinib hydrochloride
ERLOTINIB HYDROCHLORIDE
erlotinib hydrochloride (ERLOTINIB HYDROCHLORIDE) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — erlotinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
erlotinib hydrochloride (ERLOTINIB HYDROCHLORIDE) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is erlotinib hydrochloride?
erlotinib hydrochloride (ERLOTINIB HYDROCHLORIDE) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for erlotinib hydrochloride?
ERLOTINIB HYDROCHLORIDE is a marketed brand name for erlotinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erlotinib hydrochloride?
erlotinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.